Compile Data Set for Download or QSAR
maximum 50k data
Found 426 with Last Name = 'remillard' and Initial = 'r'
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176047(US10047103, 80 | US9688695, 80)
Affinity DataIC50:  0.940nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176041(US10047103, 74 | US9688695, 74)
Affinity DataIC50:  0.960nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176255(US10047103, 288 | US9688695, 288)
Affinity DataIC50:  1nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176015(US10047103, 48 | US9688695, 48)
Affinity DataIC50:  1.20nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM175995(US10047103, 75 | US9605024, Example 28 | US9688695...)
Affinity DataIC50:  1.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176048(US10047103, 81 | US9688695, 81)
Affinity DataIC50:  1.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176268(US10047103, 301 | US9688695, 301)
Affinity DataIC50:  1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176044(US10047103, 77 | US9688695, 77)
Affinity DataIC50:  1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176040(US10047103, 73 | US9688695, 73)
Affinity DataIC50:  1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176093(US10047103, 126 | US9688695, 126 | US9688695, 127)
Affinity DataIC50:  1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176272(US10047103, 305 | US9688695, 305)
Affinity DataIC50:  2nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176278(US10047103, 311 | US9688695, 311)
Affinity DataIC50:  2nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176011(US10047103, 44 | US9688695, 44)
Affinity DataIC50:  2nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176003(US10047103, 36 | US9688695, 36)
Affinity DataIC50:  2.10nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176006(US10047103, 39 | US9688695, 39)
Affinity DataIC50:  2.10nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176034(US10047103, 67 | US9688695, 67)
Affinity DataIC50:  2.20nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM175995(US10047103, 75 | US9605024, Example 28 | US9688695...)
Affinity DataIC50:  2.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM175985(US10047103, 18 | US9605024, Example 18 | US9688695...)
Affinity DataIC50:  3.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM175970(US10047103, 3 | US9605024, Example 3 | US9688695, ...)
Affinity DataIC50:  4.70nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176092(US10047103, 125 | US9688695, 125)
Affinity DataIC50:  5.70nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176061(US10047103, 94 | US9688695, 94)
Affinity DataIC50:  7.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Bristol-Myers Squibb

Curated by ChEMBL
LigandPNGBDBM50184633(6-(3,4-dichlorophenyl)-2-hydroxy-4-oxohex-2-enoic ...)
Affinity DataIC50:  10nMAssay Description:Inhibition of HIV integraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Bristol-Myers Squibb

Curated by ChEMBL
LigandPNGBDBM23399(4-{1-[(4-fluorophenyl)methyl]-1H-pyrrol-2-yl}-2,4-...)
Affinity DataIC50:  20nMAssay Description:Inhibition of HIV integraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176176(US10047103, 209 | US9688695, 209)
Affinity DataIC50:  23nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176023(US10047103, 56 | US9688695, 56)
Affinity DataIC50:  23nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176104(US10047103, 137 | US9688695, 137)
Affinity DataIC50:  23nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176108(US10047103, 141 | US9688695, 141)
Affinity DataIC50:  24nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176070(US10047103, 103 | US9688695, 103)
Affinity DataIC50:  24nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176186(US10047103, 219 | US9688695, 219)
Affinity DataIC50:  25nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176085(US10047103, 118 | US9688695, 118)
Affinity DataIC50:  25nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176118(US10047103, 151 | US9688695, 151)
Affinity DataIC50:  26nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176106(US10047103, 139 | US9688695, 139)
Affinity DataIC50:  26nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176128(US10047103, 161 | US9688695, 161)
Affinity DataIC50:  27nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176088(US10047103, 121 | US9688695, 121)
Affinity DataIC50:  27nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176060(US10047103, 93 | US9688695, 93)
Affinity DataIC50:  27nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176159(US10047103, 192 | US9688695, 192)
Affinity DataIC50:  28nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176119(US10047103, 152 | US9688695, 152)
Affinity DataIC50:  28nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176082(US10047103, 115 | US9688695, 115)
Affinity DataIC50:  28nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176112(US10047103, 145 | US9688695, 145)
Affinity DataIC50:  29nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176000(US10047103, 33 | US9605024, Example 33 | US9688695...)
Affinity DataIC50:  38nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM175969(US10047103, 2 | US9605024, Example 2 | US9688695, ...)
Affinity DataIC50:  49nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Bristol-Myers Squibb

Curated by ChEMBL
LigandPNGBDBM107693((2Z)-4-(5-chloro-1H-indol-3-yl)-2-hydroxy-4-oxobut...)
Affinity DataIC50:  80nMAssay Description:Inhibition of HIV integraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetP-selectin(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50061136((2S,3R,4E)-3-(Benzoyloxy)-2-(hexadecanoylamino)-1-...)
Affinity DataIC50:  100nMAssay Description:In vitro inhibitory concentration against Selectin P in a cell-free binding assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetP-selectin(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50369315(CHEMBL1627019)
Affinity DataIC50:  100nMAssay Description:In vitro inhibitory concentration against Selectin P in a cell-free binding assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetP-selectin(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50061124((2S,3R,4E)-3-(Benzoyloxy)-2-(hexadecanoylamino)-1-...)
Affinity DataIC50:  100nMAssay Description:In vitro inhibitory concentration against Selectin P in a cell-free binding assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetP-selectin(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50061130((2S,3R,4E)-3-(Benzoyloxy)-2-(hexadecanoylamino)-1-...)
Affinity DataIC50:  100nMAssay Description:In vitro inhibitory concentration against Selectin P in a cell-free binding assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProthrombin(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM176168(US10047103, 201 | US9688695, 201)
Affinity DataIC50:  156nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Bristol-Myers Squibb

Curated by ChEMBL
LigandPNGBDBM50184626(6-(2-chlorophenyl)-2,4,6-trioxohexanoic acid | CHE...)
Affinity DataIC50:  200nMAssay Description:Inhibition of HIV integraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Bristol-Myers Squibb

Curated by ChEMBL
LigandPNGBDBM23399(4-{1-[(4-fluorophenyl)methyl]-1H-pyrrol-2-yl}-2,4-...)
Affinity DataIC50:  300nMAssay Description:Inhibition of HIV1 recombinant integraseMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetP-selectin(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50061125((2S,3R,4E)-2-(hexadecanoylamino)-3-(benzoyloxy)-1-...)
Affinity DataIC50:  400nMAssay Description:In vitro inhibitory concentration against Selectin P in a cell-free binding assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 426 total ) | Next | Last >>
Jump to: